Is Ionis Pharmaceuticals Inc (IONS) a risky stock?
As of July 27, 2026, Clavix grades Ionis Pharmaceuticals Inc (IONS) D- for risk, a composite score of 38 out of 100 on an A+ to F scale, which puts IONS in the "elevated risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
IONS price, last 3 months
IONS's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.
The five risk dimensions behind IONS's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how IONS scores on each, as of July 27, 2026.
What's moving IONS's risk right now
Company-specific signals Clavix flags behind IONS's current grade, drawn from recent news and filings as of July 27, 2026.
The loss of a key late-stage cardiovascular asset undermines IONS's near-term pipeline value, increases legal/regulatory risk from the shareholder probe, and forces investors to v…
Investors should brace for a likely year-over-year earnings decline in Q2, which could pressure IONS shares in the near term unless the company provides stronger forward guidance.
Recent IONS news
The latest headlines Clavix ingested for Ionis Pharmaceuticals Inc, newest first. These feed the news-sentiment dimension of IONS's grade.
-
Ionis Pharmaceuticals and AstraZeneca's Phase 3 CARDIO-TTRansform trial of eplontersen for transthyretin amyloidosis cardiomyopathy failed to meet its primary efficacy endpoint, and shareholders are investigating the transparency of the trial's data and design.
-
Ionis Pharmaceuticals' eplontersen CARDIO-TTRansform trial missed its primary endpoint, while the company initiated dosing in a new ASCEND study for Dravet syndrome candidate ION337.
What a D- grade means
On the Clavix A+ to F scale, IONS's composite of 38 falls in the D band (35–49), read as "elevated risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell IONS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.